Company intelligence / Profile preview

BioPorto

Ownership: Public · BIOPOR
Employees: ~48
Development stage: Other

Overview

BioPorto has developed The NGAL Test™ which is CE-marked and available for in vitro diagnostic use in the EU, registered in Canada, Korea, Israel and other countries. ProNephro AKI (NGAL) is FDA-cleared for pediatric acute kidney injury risk assessment in the US, with commercial availability expected in 2025 through Roche Diagnostics.[1][2]

Therapeutic areas: Nephrology
Modalities: Biomarker testsantibodiesimmunoassays
Industry: Protein Biomarker Diagnostics

Partnerships

Roche Diagnostics

Beyond the preview

Go deeper on BioPorto.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPorto.

Explore the full profile